Genetic testing company Natera (NASDAQ:NTRA). will be reporting earnings tomorrow after market hours. Here’s what you need to know.

Natera beat analysts’ revenue expectations by 8.6% last quarter, reporting revenues of $476.1 million, up 53% year on year. It was a stunning quarter for the company, with a solid beat of analysts’ EPS estimates and full-year revenue guidance exceeding analysts’ expectations.

Is Natera a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Natera’s revenue to grow 21.3% year on year to $446.1 million, slowing from the 52.1% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.66 per share.Natera Total Revenue

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Natera has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 12% on average.

Looking at Natera’s peers in the immuno-oncology segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Incyte delivered year-on-year revenue growth of 19.5%, beating analysts’ expectations by 6.4%, and Exact Sciences reported revenues up 10.9%, topping estimates by 2.7%. Incyte traded up 5.3% following the results while Exact Sciences was also up 9.4%.

Read our full analysis of Incyte’s results here and Exact Sciences’s results here.

There has been positive sentiment among investors in the immuno-oncology segment, with share prices up 5.9% on average over the last month. Natera is up 19.1% during the same time and is heading into earnings with an average analyst price target of $187.72 (compared to the current share price of $157.49).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.